Accordingly, one of the most important studies for evaluating the pharmacogenetic influence in IBD is the PANTS prospective study [14], an investigation that helped identify SNPs in the HLA-DQA1*05 allele, which is related to increased immunogenicity risk in patients with CD undergoing anti-TNF-α therapy [31,44]. Here, TNF is linked to inflammatory bowel disease.